XML 32 R26.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Reporting (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Segment Reporting [Abstract] |
Financial Information of Reportable Segment | Financial information of the Company’s reportable segment for the three and six months ended June 30, 2026 and 2025 is as follows (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
Research and development ("R&D") programs: |  |  |  |  |  |  |  |  |  |  |  |
CLN-049 |  | $ | 6,009 |  |  | $ | 4,898 |  |  | $ | 11,068 |  |  | $ | 8,793 |
CLN-617 |  |  | 79 |  |  |  | 1,403 |  |  |  | 764 |  |  |  | 3,196 |
CLN-619 |  |  | 1,102 |  |  |  | 7,317 |  |  |  | 3,573 |  |  |  | 13,435 |
CLN-978 |  |  | 10,532 |  |  |  | 5,393 |  |  |  | 20,197 |  |  |  | 10,066 |
Early-stage programs |  |  | 1,116 |  |  |  | 1,986 |  |  |  | 1,825 |  |  |  | 3,008 |
Velinotamig |  |  | 3,951 |  |  |  | 10 |  |  |  | 6,754 |  |  |  | 10 |
Zipalertinib |  |  | 8,273 |  |  |  | 6,001 |  |  |  | 15,206 |  |  |  | 16,161 |
Total R&D program expense |  |  | 31,062 |  |  |  | 27,008 |  |  |  | 59,387 |  |  |  | 54,669 |
Equity-based compensation |  |  | 8,447 |  |  |  | 9,887 |  |  |  | 16,063 |  |  |  | 19,261 |
R&D personnel and operations |  |  | 9,070 |  |  |  | 9,741 |  |  |  | 18,909 |  |  |  | 19,572 |
General and administrative personnel |  |  | 3,589 |  |  |  | 3,335 |  |  |  | 7,384 |  |  |  | 6,824 |
License agreement obligations |  |  | — |  |  |  | 20,115 |  |  |  | — |  |  |  | 20,153 |
Other segment expenses(1) |  |  | 5,086 |  |  |  | 5,712 |  |  |  | 9,208 |  |  |  | 10,315 |
Loss from operations |  |  | (57,254 | ) |  |  | (75,798 | ) |  |  | (110,951 | ) |  |  | (130,794 | )
Interest income |  |  | 3,648 |  |  |  | 5,924 |  |  |  | 7,746 |  |  |  | 12,504 |
Other expense, net |  |  | (98 | ) |  |  | (181 | ) |  |  | (160 | ) |  |  | (266 | )
Net loss |  | $ | (53,704 | ) |  | $ | (70,055 | ) |  | $ | (103,365 | ) |  | $ | (118,556 | )
(1) Other segment expenses for the three and six months ended June 30, 2026 and 2025 include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; marketing expenses; depreciation; and other operating costs.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration